Autologous Adipose-Derived Mesenchymal Stromal Cells for Osteoarthritis

"Autologous Adipose-Derived Mesenchymal Stromal Cells have limited data regarding safety and efficacy, thus it is assigned a score of 1 on our team's scale."

"This clinical trial is welcoming 24 participants with knee osteoarthritis who are between 40 and 70 years old. The key criteria for applicants include successfully completing a 6 week or longer course of conservative treatments (such as activity modification, weight loss, physical therapy etc), being female of childbearing potential but having tested negative on the pregnancy test prior to receiving study drug & agreeing to use adequate contraception from screening until one year post-treatment cycle completion, unilateral symptomatic primary femorotibial OA radiographically proven by two investigators at least KL grade 2 accompanied by joint space narrowing, ability to walk without assistance regularly, clinically stable target knee not"

"Unfortunately, this trial is no longer recruiting new participants. The study was initially announced on October 26th 2016 and had its last update published April 4th 2022. If you are still looking for research opportunities, there are 692 studies exploring osteoarthritis of the knee actively enrolling as well 33 trials studying Autologous Adipose-Derived Mesenchymal Stromal Cells searching for volunteers."

"This medical trial is not presently recruiting; its first post was on October 26th 2016, and it has been updated most recently on April 4th 2022. For those looking for other related studies, 692 clinical trials are actively enrolling patients with osteoarthritis of the knee while 33 autologous adipose-derived mesenchymal stromal cell studies are also seeking participants."

"The study requires that applicants are aged between 40 and 70, with 41 trials for minors and 684 specifically tailored to citizens over 65."